title: Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.
abstract: OBJECTIVE
  We designed and conducted a randomized single-institution trial comparing two common prophylactic platelet transfusion thresholds in patients undergoing induction therapy for acute leukemia.
  
  
  METHODS
  Seventy-eight patients undergoing induction therapy for acute leukemia were randomized to receive prophylactic apheresis platelet concentrates when the platelet count was either < or = 10,000/microL or < or = 20,000/microL.
  
  
  RESULTS
  There was no significant difference in the total number of bleeding episodes per patient with a median of four in the < or = 10,000/microL arm and two in the < or = 20,000/microL arm (25th to 75th percentiles of 2, 7 and 1, 5, respectively; P = .12). Patients randomized to the < or = 10,000/microL arm received more platelet transfusions for bleeding [one (0, 2) v zero (0, 0); P = .0003]. In contrast, patients on the < or = 20,000/microL arm received more platelet transfusions for prophylactic indications [10 (5, 14) v six (3, 8); P = 0.001], as would be expected, but less for bleeding. Nevertheless, the total number of platelet transfusions given to patients on the < or = 20,000/microL arm was higher and nearly significant [11 (6, 15) v seven (5, 11); P = .07]. There were no statistically significant differences between the groups with regard to RBC transfusion requirements, febrile days, days hospitalized, days thrombocytopenic, need for HLA-matched platelets, remission rate, or death during induction chemotherapy. No patient in either group died from hemorrhage or underwent major surgery for bleeding complications.
  
  
  CONCLUSIONS
  Giving prophylactic platelets at a threshold of < or = 10,000/microL compared with < or = 20,000/microL can decrease the total utilization of platelets with only a small adverse effect on bleeding, and no statistically significant effect on morbidity.
authors.affiliation: Department of Medicine, The University of Iowa College of Medicine, Iowa City 52242, USA.
authors.forename: K D
authors.initials: KD
authors.lastname: Heckman
authors.forename: G J
authors.initials: GJ
authors.lastname: Weiner
authors.forename: C S
authors.initials: CS
authors.lastname: Davis
authors.forename: R G
authors.initials: RG
authors.lastname: Strauss
authors.forename: M P
authors.initials: MP
authors.lastname: Jones
authors.forename: C P
authors.initials: CP
authors.lastname: Burns
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007938:Leukemia / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D017713:Platelet Transfusion / Q000706:statistics & numerical data; D011446:Prospective Studies; D012074:Remission Induction